... These include: Rituximab (Rituxan) — A very common CLL treatment that may be used alone or with chemotherapy or other targeted therapies Obinutuzumab (Gazyva) — Used as an initial CLL treatment along with other cancer medications, or alone when other treatments are ineffective Moxetumomab pasudotox (Lumoxiti) — Used in the treatment of hairy cell leukemia ...
... These include: Rituximab (Rituxan) — A very common CLL treatment that may be used alone or with chemotherapy or other targeted therapies Obinutuzumab (Gazyva) — Used as an initial CLL treatment along with other cancer medications, or alone when other treatments are ineffective Moxetumomab pasudotox (Lumoxiti) — Used in the treatment of hairy cell leukemia ...
... Lumoxiti (moxetumomab pasudotox) is a targeted therapy drug approved by the U.S. Food and Drug Administration to treat HCL. People who have previously tried at least two other treatments, including either pentostatin or cladribine, can typically try moxetumomab. ...
... Lumoxiti (moxetumomab pasudotox) is a targeted therapy drug approved by the U.S. Food and Drug Administration to treat HCL. People who have previously tried at least two other treatments, including either pentostatin or cladribine, can typically try moxetumomab. ...
... Lumoxiti (moxetumomab pasudotox-tdfk) is approved by the FDA to treat HCL. This medication — which blocks a protein called CD22 — may also be helpful for treating B-cell prolymphocytic leukemia (PLL). ...
... Lumoxiti (moxetumomab pasudotox-tdfk) is approved by the FDA to treat HCL. This medication — which blocks a protein called CD22 — may also be helpful for treating B-cell prolymphocytic leukemia (PLL). ...
Join